Our robust pipeline comprises high value proprietary assets.
To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.
NVG-111 is a first-in-class Receptor Tyrosine Kinase Like Orphan Like Receptor 1 (ROR1) bispecific antibody T-cell engager for hematological and solid tumors. Initially the NVG-111 program will focus on Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma. It is designed to be highly effective in the killing of cancer cells, without the depletion of normal B cells.
NVG-111 can target cancer initiating stem cells (CSCs), a subpopulation of cancer cells that are resistant to standard cancer therapies and is believed to be the only T cell engager in development that can kill CSCs, potentially reducing the risk of tumor recurrence. Our proprietary CD3 targeting binder has been humanized and engineered for optimal activation of T cells for the efficient killing of tumor targets without excessive release of cytokines.